Literature DB >> 10935696

Estimating the national cost of treating people with HIV disease: patient, payer, and provider data.

F J Hellinger1, J A Fleishman.   

Abstract

OBJECTIVE: Existing estimates of the national cost of treating all people with HIV disease use data from a sample of people with HIV disease to extrapolate the cost of treating all people with HIV disease (patient-based approach). This study derives estimates using two novel approaches (i.e., payer-based and provider-based) and compares these with existing estimates. DATA SOURCES: These include the Health Insurance Association of American and the American Council of Life Insurance 1996 HIV survey, the 1996 State Inpatient Databases (SID) maintained by the Agency for Healthcare Research and Quality, and the IMS America Ltd. survey of independent and chain drugstores. PRINCIPAL
FINDINGS: The cost of treating all people with HIV disease in 1996 was between $6.7 and $7.8 billion U.S., and the average annual cost of treating a person with HIV disease was between $20,000 and $24,700 U.S.
CONCLUSIONS: Analysts should derive estimates of the cost of treating people with HIV disease using several different approaches. K

Entities:  

Mesh:

Year:  2000        PMID: 10935696     DOI: 10.1097/00126334-200006010-00016

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  8 in total

1.  Cost of HIV and determinants of health care costs in HIV-positive patients in Germany: results of the DAGNÄ K3A Study.

Authors:  Sarah Mostardt; Nikola Hanhoff; Jürgen Wasem; Armin Goetzenich; Knud Schewe; Eva Wolf; Christoph Mayr; Hans Jaeger; Holger Pfaff; Stephan Dupke; Anja Neumann
Journal:  Eur J Health Econ       Date:  2012-09-19

2.  Contemporary costs of HIV healthcare in the HAART era.

Authors:  Kelly A Gebo; John A Fleishman; Richard Conviser; James Hellinger; Fred J Hellinger; Joshua S Josephs; Philip Keiser; Paul Gaist; Richard D Moore
Journal:  AIDS       Date:  2010-11-13       Impact factor: 4.177

Review 3.  Economic costs to business of the HIV/AIDS epidemic.

Authors:  Gordon G Liu; Jeff J Guo; Scott R Smith
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

4.  The lifetime medical cost savings from preventing HIV in the United States.

Authors:  Bruce R Schackman; John A Fleishman; Amanda E Su; Bethany K Berkowitz; Richard D Moore; Rochelle P Walensky; Jessica E Becker; Cindy Voss; A David Paltiel; Milton C Weinstein; Kenneth A Freedberg; Kelly A Gebo; Elena Losina
Journal:  Med Care       Date:  2015-04       Impact factor: 2.983

5.  Limited spending: an analysis of correctional expenditures on antiretrovirals for HIV-infected prisoners.

Authors:  Nick Zaller; Portia Thurmond; Josiah D Rich
Journal:  Public Health Rep       Date:  2007 Jan-Feb       Impact factor: 2.792

6.  Cost of Care for HIV-Infected Patients with Co-Occurring Substance Use Disorder or Psychiatric Disease: Report from a Large, Integrated Health Plan.

Authors:  Gerald N DeLorenze; Ai-Lin Tsai; Michael A Horberg; Charles P Quesenberry
Journal:  AIDS Res Treat       Date:  2014-06-22

7.  Early and late direct costs in a Southern African antiretroviral treatment programme: a retrospective cohort analysis.

Authors:  Rory Leisegang; Susan Cleary; Michael Hislop; Alistair Davidse; Leon Regensberg; Francesca Little; Gary Maartens
Journal:  PLoS Med       Date:  2009-12-01       Impact factor: 11.069

8.  Analysis of contemporary HIV/AIDS health care costs in Germany: Driving factors and distribution across antiretroviral therapy lines.

Authors:  Marina Treskova; Alexander Kuhlmann; Johannes Bogner; Martin Hower; Hans Heiken; Hans-Jürgen Stellbrink; Jörg Mahlich; Johann-Matthias Graf von der Schulenburg; Matthias Stoll
Journal:  Medicine (Baltimore)       Date:  2016-06       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.